-- Astellas Says Full-Year Profit Rose 16% Vesicare Sales
-- B y   K a n o k o   M a t s u y a m a
-- 2012-05-10T05:07:46Z
-- http://www.bloomberg.com/news/2012-05-10/astellas-says-full-year-profit-rose-16-vesicare-sales.html
Astellas Pharma Inc. (4503) , Japanâ€™s third-
largest drugmaker, said full-year profit rose 16 percent, led by
higher sales of urinary disorder treatment Vesicare.  Net income  rose to 78.2 billion yen ($981 million), or
169.4 yen a share, in the 12 months ended March from 67.7
billion yen, or 146.5 yen a share, a year earlier, Tokyo-based
Astellas said in a statement today. Profit was expected to rise
to 87.6 billion yen, according to the average of 14  analyst
estimates  compiled by Bloomberg.  To contact the reporter on this story:
Kanoko Matsuyama in  Tokyo  at 
 kmatsuyama2@bloomberg.net .  To contact the editor responsible for this story:
Jason Gale in Melbourne at 
 j.gale@bloomberg.net  